Literature DB >> 27208374

Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study.

Nathan D Wong1, Yanglu Zhao2, Rohini Patel3, Christopher Patao3, Shaista Malik3, Alain G Bertoni4, Adolfo Correa5, Aaron R Folsom6, Sumesh Kachroo7, Jayanti Mukherjee7, Herman Taylor5, Elizabeth Selvin8.   

Abstract

OBJECTIVE: Controlling cardiovascular disease (CVD) risk factors in diabetes mellitus (DM) reduces the number of CVD events, but the effects of multifactorial risk factor control are not well quantified. We examined whether being at targets for blood pressure (BP), LDL cholesterol (LDL-C), and glycated hemoglobin (HbA1c) together are associated with lower risks for CVD events in U.S. adults with DM. RESEARCH DESIGN AND METHODS: We studied 2,018 adults, 28-86 years of age with DM but without known CVD, from the Atherosclerosis Risk in Communities (ARIC) study, Multi-Ethnic Study of Atherosclerosis (MESA), and Jackson Heart Study (JHS). Cox regression examined coronary heart disease (CHD) and CVD events over a mean 11-year follow-up in those individuals at BP, LDL-C, and HbA1c target levels, and by the number of controlled risk factors.
RESULTS: Of 2,018 DM subjects (43% male, 55% African American), 41.8%, 32.1%, and 41.9% were at target levels for BP, LDL-C, and HbA1c, respectively; 41.1%, 26.5%, and 7.2% were at target levels for any one, two, or all three factors, respectively. Being at BP, LDL-C, or HbA1c target levels related to 17%, 33%, and 37% lower CVD risks and 17%, 41%, and 36% lower CHD risks, respectively (P < 0.05 to P < 0.0001, except for BP in CHD risk); those subjects with one, two, or all three risk factors at target levels (vs. none) had incrementally lower adjusted risks of CVD events of 36%, 52%, and 62%, respectively, and incrementally lower adjusted risks of CHD events of 41%, 56%, and 60%, respectively (P < 0.001 to P < 0.0001). Propensity score adjustment showed similar findings.
CONCLUSIONS: Optimal levels of BP, LDL-C, and HbA1c occurring together in individuals with DM are uncommon, but are associated with substantially lower risk of CHD and CVD.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27208374      PMCID: PMC4839178          DOI: 10.2337/dc15-2439

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  34 in total

1.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).

Authors:  G C Fonarow; A Gawlinski; S Moughrabi; J H Tillisch
Journal:  Am J Cardiol       Date:  2001-04-01       Impact factor: 2.778

2.  Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000.

Authors:  Giuseppina Imperatore; Betsy L Cadwell; Linda Geiss; Jinan B Saadinne; Desmond E Williams; Earl S Ford; Theodore J Thompson; K M Venkat Narayan; Edward W Gregg
Journal:  Am J Epidemiol       Date:  2004-09-15       Impact factor: 4.897

3.  Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study.

Authors:  Myra A Carpenter; Richard Crow; Michael Steffes; William Rock; Jeffrey Heilbraun; Gregory Evans; Thomas Skelton; Robert Jensen; Daniel Sarpong
Journal:  Am J Med Sci       Date:  2004-09       Impact factor: 2.378

Review 4.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

5.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 6.  2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations.

Authors:  Lawrence R Krakoff; Robert L Gillespie; Keith C Ferdinand; Icilma V Fergus; Ola Akinboboye; Kim A Williams; Mary Norine Walsh; C Noel Bairey Merz; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2014-07-29       Impact factor: 24.094

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 8.  Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.

Authors:  Caroline S Fox; Sherita Hill Golden; Cheryl Anderson; George A Bray; Lora E Burke; Ian H de Boer; Prakash Deedwania; Robert H Eckel; Abby G Ershow; Judith Fradkin; Silvio E Inzucchi; Mikhail Kosiborod; Robert G Nelson; Mahesh J Patel; Michael Pignone; Laurie Quinn; Philip R Schauer; Elizabeth Selvin; Dorothea K Vafiadis
Journal:  Circulation       Date:  2015-08-05       Impact factor: 29.690

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

View more
  37 in total

1.  Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Nathan D Wong; Yanglu Zhao; Ruben G W Quek; Roger S Blumenthal; Matthew J Budoff; Mary Cushman; Parveen Garg; Veit Sandfort; Michael Tsai; J Antonio G Lopez
Journal:  J Clin Lipidol       Date:  2017-06-30       Impact factor: 4.766

Review 2.  Impact of Conventional Stroke Risk Factors on Stroke in Women: An Update.

Authors:  Tracy E Madsen; Virginia J Howard; Monik Jiménez; Kathryn M Rexrode; Maria Czarina Acelajado; Dawn Kleindorfer; Seemant Chaturvedi
Journal:  Stroke       Date:  2018-02-08       Impact factor: 7.914

Review 3.  Cardiovascular risk assessment and screening in diabetes.

Authors:  Yanglu Zhao
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

Review 4.  The emergence of cardiodiabetology.

Authors:  Paul D Rosenblit; Norman E Lepor; Nathan D Wong
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

5.  Cardiodiabetology: The convergence of diabetes and cardiovascular disease.

Authors:  Nathan D Wong
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

6.  Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed.

Authors:  Manel Mata-Cases; Josep Franch-Nadal; Mònica Gratacòs; Dídac Mauricio
Journal:  Diabetes Spectr       Date:  2020-02

Review 7.  Diabetes Complications in Racial and Ethnic Minority Populations in the USA.

Authors:  J Sonya Haw; Megha Shah; Sara Turbow; Michelle Egeolu; Guillermo Umpierrez
Journal:  Curr Diab Rep       Date:  2021-01-09       Impact factor: 4.810

Review 8.  The Experience of Partners of Adults with Type 1 Diabetes: an Integrative Review.

Authors:  Robin Whittemore; Roberta Delvy; Margaret M McCarthy
Journal:  Curr Diab Rep       Date:  2018-03-03       Impact factor: 4.810

9.  Hypertriglyceridemic waist phenotype and abnormal glucose metabolism: a system review and meta-analysis.

Authors:  Chun-Ming Ma; Xiao-Li Liu; Na Lu; Rui Wang; Qiang Lu; Fu-Zai Yin
Journal:  Endocrine       Date:  2019-05-07       Impact factor: 3.633

10.  SES and correlated factors do not explain the association between periodontal disease, edentulism, and cancer risk.

Authors:  Jiayun Lu; Ina Zaimi; John R Barber; Corinne E Joshu; Anna E Prizment; James D Beck; Elizabeth A Platz; Dominique S Michaud
Journal:  Ann Epidemiol       Date:  2019-08-22       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.